AZ agrees $2bn deal to buy radiopharma firm Fusion
AstraZeneca has upgraded a 2020 alliance with Fusion Pharma focusing on radioconjugate therapies for cancer, opting to buy the firm outright in a deal worth around $2 bill
Orchard's gene therapy for MLD finally gets US approval
The FDA has cleared its first gene therapy for kids with metachromatic leukodystrophy (MLD), a rare genetic disorder of the brain and nervous centre.
BMS completes $14bn takeover of Karuna
Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha
NHS will expand use of waiting list-busting AI after pilot
Artificial intelligence software designed to tackle missed appointments and reduce waiting lists will see its use by the NHS ramp up after a successful pilot deployment.
Havas Lynx takes three Golds at PM Society Awards 2024
The PM Society’s 38th annual awards were held last week, on Friday 15th March, at the JW Marriott Grosvenor House London, at which over 900 industry professionals came tog
Partner Content
Pre-Filled Syringes West Coast Conference
SAE Media Group’s 8th Annual Pre-Filled Syringes West Coast Conference will be back for 2024 in the West Coast to bring together device developers, biotech and big pharma.
Injectable Drug Delivery Conference and Exhibition
Injectable Drug Delivery is an industry focused on two overarching topics the development of the device & the interaction between drug product and device.
6th Cell Engager Therapeutics Summit 2024
Advancing the Development of Novel Targets, Safe, & Effective Multi-Specific Immune Cell Engagers for Solid & Liquid Tumors in the Clinic
4th mRNA-Based Therapeutics Summit
Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to Commercialisation by Ensuring Targeted Delivery, Durability & Tolerable Immunogenicity Across All Disease Indica
The Brand-New Peptide Based Therapeutics Summit - Boston, MA
First event dedicated to designing, synthesising & identifying the optimal peptide-based drugs